검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Genetical Recombination (Brentuximab Vedotin, Brentuximab Vedotin (Genetical Recombination)) Seagen / Takeda·Peripheral T Cell Lymphoma ORR 91.7% |
|---|---|
Overview Program | Brentuximab Vedotin (Genetical Recombination) |
Overview Company | Seagen / Takeda |
Overview Modality | ADC |
Overview Target | Peripheral T Cell Lymphoma |
Overview Indication | Untreated CD30-Positive Hodgkin's Lymphoma |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen |
MoA Biomarker | biomarkers for HBsAg clearance and responses to Peg-IFN-α in HBeAg-negative chronic hepatitis B patient |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Cynomolgus monkey, Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat, NHP |
Toxicology Major finding | Hepatotoxicity : Monitor liver enzymes and bilirubin ( 5 |
Clinical Primary efficacy | ORR 91.7% |
Clinical ORR | 91.7% |
Clinical PFS | 4.9 |
Clinical OS | 14.3 |
Clinical Result source | ClinicalTrials.gov NCT02594163 |
Clinical Data Tier / Score | A · 58 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Genetical Recombination (Brentuximab Vedotin, Brentuximab Vedotin (Genetical Recombination)) Seagen / Takeda·Peripheral T Cell Lymphoma ORR 91.7% |
|---|---|
Overview Program | Brentuximab Vedotin (Genetical Recombination) |
Overview Company | Seagen / Takeda |
Overview Modality | ADC |
Overview Target | Peripheral T Cell Lymphoma |
Overview Indication | Untreated CD30-Positive Hodgkin's Lymphoma |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen |
MoA Biomarker | biomarkers for HBsAg clearance and responses to Peg-IFN-α in HBeAg-negative chronic hepatitis B patient |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Cynomolgus monkey, Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat, NHP |
Toxicology Major finding | Hepatotoxicity : Monitor liver enzymes and bilirubin ( 5 |
Clinical Primary efficacy | ORR 91.7% |
Clinical ORR | 91.7% |
Clinical PFS | 4.9 |
Clinical OS | 14.3 |
Clinical Result source | ClinicalTrials.gov NCT02594163 |
Clinical Data Tier / Score | A · 58 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
추천 비교
추천 비교